Advanced Solid Tumor study: CX-5461
Official title Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
ClinicalTrials.gov ID: NCT04890613
What this study is testing
What is CX-5461?
CX-5461 is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for advanced solid tumor.
Also referred to as Pidnarulex.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find a safe dose of CX-5461 and see early signs it might shrink tumors, while also checking quality of life and biological markers.
- Who it's for
- Adults with advanced solid tumors who have a BRCA1, BRCA2, PALB2 or other homologous recombination deficiency mutation.
- What's involved
- Participants receive an IV infusion of CX-5461 on Day 1 and Day 8 of each 28‑day cycle, attend regular clinic visits for safety checks, blood draws, and complete quality‑of‑life questionnaires.
- Time commitment
- The trial runs for multiple 28‑day cycles until a tolerable dose is identified, with clinic visits every four weeks for infusions and assessments.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytologically confirmed malignancy of the pancreas, prostate, breast, or ovary.
- Histologically confirmed ovarian, fallopian tube or primary peritoneal cancer, with a high grade serous or high grade endometrioid histology subtype.
- Documented evidence of pathogenic or likely pathogenic germline mutation or a clinically actionable somatic mutation in BRCA1 and/or other...
- Platinum Sensitive with no evidence of disease progression within 6 months of the last dose of platinum-based chemotherapy (n=10 patients); OR
- Age ≥ 18 years.
You likely can't join if
- For pancreatic cancer; non-adenocarcinoma histology is excluded from this study.
- Patients with malignant bowel obstruction.
- Untreated, unstable brain or meningeal metastases or tumor. Patients with radiological evidence of stable brain metastases are eligible provided that...
- Unresolved toxicity \> CTCAE grade 1 from previous anti-cancer therapy (including radiotherapy) except hematological toxicity, Grade 1 or 2...
- Any evidence of severe or uncontrolled diseases such as but not limited to active infection, unstable or uncompensated respiratory, cardiac...
- Treatment with an investigational (non-registered - other than PARP inhibitor) agent within 30 days and treatment with PARP inhibitor within 14 days...
See the full eligibility criteria
- Histologically or cytologically confirmed malignancy of the pancreas, prostate, breast, or ovary.
- Histologically confirmed ovarian, fallopian tube or primary peritoneal cancer, with a high grade serous or high grade endometrioid histology subtype.
- Documented evidence of pathogenic or likely pathogenic germline mutation or a clinically actionable somatic mutation in BRCA1 and/or other HRD-associated mutation, as indicated in a CLIA-certified laboratory report.
- Platinum Sensitive with no evidence of disease progression within 6 months of the last dose of platinum-based chemotherapy (n=10 patients); OR
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 within 14 days of registration.
- Radiographically documented disease progression within 28 days of registration and evaluable as per RECIST v1.1.
- Patient must have measurable disease as per RECIST v1.1.
- Absolute Neutrophil Count ≥ 1.5 x 10\^9/L
- Platelets ≥ 100 x 10\^9/L
- Hemoglobin ≥ 9 g/dL (blood transfusion ≤ 7 days of screening not permitted).
- Calculated creatinine clearance \> 51mL/min (Cockcroft-Gault formula)
- AST/ALT ≤ 2.5× the upper limit of normal (ULN). people with liver metastasis may have AST, ALP, and ALT ≤ 5.0 X ULN.
- Bilirubin ≤ 1.5×ULN. This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology)...
- INR/PT and aPTT ≤1.5 X ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
- Albumin ≥3.0 g/dL
- Patients are willing to undergo tumour biopsy pre-treatment and at time of progression on treatment.
- Life expectancy of greater than 3 months from the date of registration.
- Able to provide written informed consent.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration.
- Female patients of childbearing potential and male patients who are sexually active must agree to practice true abstinence or at least two effective methods of contraception (ie: condoms with spermicide, hormonal...
- There is no minimum or maximum number of lines of prior therapy and prior PARP inhibitor therapy is allowed.
- Patient is clinically stable at the time of entering the study.
- For pancreatic cancer; non-adenocarcinoma histology is excluded from this study.
- Patients with malignant bowel obstruction.
- Untreated, unstable brain or meningeal metastases or tumor. Patients with radiological evidence of stable brain metastases are eligible provided that they are asymptomatic and either do not require corticosteroids or...
- Unresolved toxicity \> CTCAE grade 1 from previous anti-cancer therapy (including radiotherapy) except hematological toxicity, Grade 1 or 2 neuropathy, and alopecia.
- Any evidence of severe or uncontrolled diseases such as but not limited to active infection, unstable or uncompensated respiratory, cardiac, neurological, hepatic, renal disease or psychiatric illness/social situations...
- Treatment with an investigational (non-registered - other than PARP inhibitor) agent within 30 days and treatment with PARP inhibitor within 14 days prior to the first dose of study medication.
- Immuno-compromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e., hepatitis B or C).
- Patients who have had recent (within 14 days of registration, or until any wound has completely healed) major thoracic or abdominal surgery prior to study start, or a surgical incision that is not fully healed.
- No concurrent systemic anti-cancer therapy, biological therapy or other novel agent is to be permitted. Palliative radiotherapy may be allowed.
- Patients may be potentially eligible where the current tissue diagnosis is confirmed histologically from biopsy of a target lesion, and the patient has had no evidence of active second malignancy which requires...
- Presence of known photosensitivity disorders (xeroderma pigmentosa, porphyria etc.). Strict adherence to protocol-defined sun-protection measures is essential for the duration of study.
- Female patients who are pregnant or nursing.
- Ophthalmological active ocular surface disease at baseline (based on ophthalmological evaluation).
- History of cicatricial conjunctivitis (as evaluation by an ophthalmologist).
- Has had radiotherapy with a limited field for palliation within 1 week of the first dose of study drug, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of...
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms).
- A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of long QT syndrome).
- The use of concomitant medications that prolong the QT/QTc interval.
- Patients with the use of strong CYP3A4 inhibitor or inducer.
- Other malignancies within 5 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin, or ductal carcinoma in situ of the breast that has been surgically cured.
The study team makes the final eligibility decision.
Where it is enrolling
- Santa Monica, California, United States
- Tampa, Florida, United States
- Boston, Massachusetts, United States
- Columbus, Ohio, United States
- Pittsburgh, Pennsylvania, United States
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Santa Monica, California, United States; Tampa, Florida, United States; Boston, Massachusetts, United States; Columbus, Ohio, United States; Pittsburgh, Pennsylvania, United States; Toronto, Ontario, Canada and 1 more location. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.